Before presenting my ASH summary, I’ll mention a late-breaking abstract presentation that I attended early this morning focused on different transplant regimens. This was a large trials (750 newly diagnosed multiple myeloma patients) randomly divided into three arms. Arm 1, denote ACM, received one autologous stem cell transplant (ASCT), four cycles of Velcade-Revlimid-dexamethasone consolidation, then […]